197 related articles for article (PubMed ID: 12017673)
1. Implications of the United Kingdom Prospective Diabetes Study.
American Diabetes Association
Diabetes Care; 2000 Jan; 23 Suppl 1():S27-31. PubMed ID: 12017673
[No Abstract] [Full Text] [Related]
2. Implications of the Diabetes Control and Complications Trial.
American Diabetes Association
Diabetes Care; 2000 Jan; 23 Suppl 1():S24-6. PubMed ID: 12017672
[No Abstract] [Full Text] [Related]
3. Metformin plus glyburide combination as initial therapy in type 2 diabetes: one month follow-up.
Medina Santillán R; Reyes-García G; Mateos-García E
Proc West Pharmacol Soc; 2002; 45():137-8. PubMed ID: 12434558
[No Abstract] [Full Text] [Related]
4. [Fasting hyperglycemia and postprandial glucose peaks. Diabetes therapy mustact on 2 sides].
MMW Fortschr Med; 2003 Aug; 145(33-34):59. PubMed ID: 14526583
[No Abstract] [Full Text] [Related]
5. Metformin in the management of type 2 diabetes.
Howlett HC
Diabet Med; 1989 Mar; 6(2):179-80. PubMed ID: 2522868
[No Abstract] [Full Text] [Related]
6. Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management.
Halimi S
Diabetes Metab; 2006 Dec; 32(6):555-6. PubMed ID: 17296508
[No Abstract] [Full Text] [Related]
7. [Optimal therapeutic strategy in type 2 diabetes mellitus].
Scherbaum WA; Nitschmann S
Internist (Berl); 2009 Feb; 50(2):244-8. PubMed ID: 19183919
[No Abstract] [Full Text] [Related]
8. Follow-up of intensive glucose control in type 2 diabetes.
Mühlhauser I
N Engl J Med; 2009 Jan; 360(4):417; author reply 418. PubMed ID: 19172674
[No Abstract] [Full Text] [Related]
9. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
10. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.
Ersoy C; Kiyici S; Budak F; Oral B; Guclu M; Duran C; Selimoglu H; Erturk E; Tuncel E; Imamoglu S
Diabetes Res Clin Pract; 2008 Jul; 81(1):56-60. PubMed ID: 18358555
[TBL] [Abstract][Full Text] [Related]
11. Metformin plus glyburide combination as therapy in failure to monotherapy in type 2 diabetic patients: one month follow-up.
Medina Santillán R; Reyes-García G; Mateos-García E
Proc West Pharmacol Soc; 2002; 45():139-40. PubMed ID: 12434559
[No Abstract] [Full Text] [Related]
12. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
[No Abstract] [Full Text] [Related]
13. Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: an Asian-Pacific perspective.
Chan JC; Deerochanawong C; Shera AS; Yoon KH; Adam JM; Ta VB; Chan SP; Fernando RE; Horn LC; Nguyen TK; Litonjua AD; Soegondo S; Zimmet P
Diabetes Res Clin Pract; 2007 Mar; 75(3):255-66. PubMed ID: 16876285
[TBL] [Abstract][Full Text] [Related]
14. [Medications for type-2 diabetes and high blood pressure].
Schröder H
Med Monatsschr Pharm; 2002 Nov; 25(11):386-8. PubMed ID: 12474347
[No Abstract] [Full Text] [Related]
15. Metformin: evidence-based versus rational pharmacotherapy.
Smits P; Tack CJ
Neth J Med; 2002 Jul; 60(6):228-30. PubMed ID: 12365465
[No Abstract] [Full Text] [Related]
16. UKPDS and beyond: into the next millennium. United Kingdom Prospective Diabetes Study.
Krentz AJ
Diabetes Obes Metab; 1999 Jan; 1(1):13-22. PubMed ID: 11221807
[No Abstract] [Full Text] [Related]
17. Metformin: diamonds are forever.
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
[TBL] [Abstract][Full Text] [Related]
18. [Changes in clinical intervention studies: when the wellbeing of the patients takes precedence].
Flórez H; Casanova P
Invest Clin; 1998 Sep; 39(3):159-61. PubMed ID: 9780550
[No Abstract] [Full Text] [Related]
19. Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus.
Chaturvedi N; Bilous R; Sjolie AK; Klein R;
Contemp Clin Trials; 2007 Nov; 28(6):780. PubMed ID: 17643353
[No Abstract] [Full Text] [Related]
20. [The practice guideline 'Diabetes mellitus type 2' (second revision) from the Dutch College of General Practitioners; a response from the perspective of general practice].
Bouma M; Rutten GE; Wiersma T
Ned Tijdschr Geneeskd; 2006 Oct; 150(42):2339-40. PubMed ID: 17091545
[No Abstract] [Full Text] [Related]
[Next] [New Search]
